Previous studies showed that the relapse rate of AML patients with DEK-NUP214 was > 80% and the 5-year survival rate was only 9% for those who did not receive allo-HSCT.[2,31] Wang et al. [32] reported that the incidence of relapse was approximately 16% in adult patients with AML receiving allo-HSCT at CR1. The gene discussed is NUP214; the disease is acute myeloid leukemia.